Search
WAVE Life Sciences Ltd
WVEAdd to Watchlist
6.260USD
+0.420+7.19%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+7.19%
5 Days
+7.38%
1 Month
+2.79%
6 Months
-60.75%
Year to Date
-63.18%
1 Year
-9.93%
Key Figures
5.860Open
6.320High
4.36MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.27%Turnover Ratio
5.840Prev. Close
5.860Low
19.74MTurnover
LossP/E Static
2.35P/B
0.00%Div Yield TTM
-42.11%ROA
21.73052wk High
1.83Volume Ratio
-97.01MNet Profit
192.34MShares
-1.0537EPS TTM
-1.16Beta
-53.72%ROE
5.02052wk Low
7.88%Amplitude
100.00%Gross Margin
1.20BMarket Cap
-0.82Reward/Risk
5.00%Risk Rate
TradingKey Stock Score of WAVE Life Sciences Ltd
Currency: USD Updated: 2026-07-02Key Insights
WAVE Life Sciences Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
WAVE Life Sciences Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
WAVE Life Sciences Ltd Highlights
StrengthsRisks
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Growing
The company is in a growing phase, with the latest annual income totaling USD 42.73M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 42.73M.
Overvalued
The company’s latest PE is -5.94, at a high 3-year percentile range.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 11.62M shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
23.000
Target Price
+293.84%
Upside Space
WAVE Life Sciences Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
WAVE Life Sciences Ltd Info
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Ticker SymbolWVE
CompanyWAVE Life Sciences Ltd
CEOBolno (Paul B)
Websitehttps://www.wavelifesciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of WAVE Life Sciences Ltd (WVE)?
The current price of WAVE Life Sciences Ltd (WVE) is 6.26.
What is the symbol of WAVE Life Sciences Ltd?
The ticker symbol of WAVE Life Sciences Ltd is WVE.
What is the 52-week high of WAVE Life Sciences Ltd?
The 52-week high of WAVE Life Sciences Ltd is 21.73.
What is the 52-week low of WAVE Life Sciences Ltd?
The 52-week low of WAVE Life Sciences Ltd is 5.02.
What is the market capitalization of WAVE Life Sciences Ltd?
The market capitalization of WAVE Life Sciences Ltd is 1.20B.
Is WAVE Life Sciences Ltd (WVE) currently rated as Buy, Hold, or Sell?
According to analysts, WAVE Life Sciences Ltd (WVE) has an overall rating of Buy, with a price target of 23.00.
What is the Earnings Per Share (EPS TTM) of WAVE Life Sciences Ltd (WVE)?
The Earnings Per Share (EPS TTM) of WAVE Life Sciences Ltd (WVE) is -1.21.